Hematopoietic Stem Cell Transplantation (HSCT) is a procedure of infusing healthy blood forming stem cells into the patient’s body for treatment of several malignant (AML, ALL, CML, lymphoma, Multiple Myelomas) and non-malignant (SCID, Sickle cell disease, Thalassemia) complications. While HSCT is a life saving treatment, it is compromised by several endothelial complications such as Transplant associated- thrombotic microangiopathy (TA-TMA), Idiopathic pulmonary syndrome (IPS), Hepatic Veno-occlusive disease (HVOD), Engraftment syndrome. These are potentially life-threatening complications that root from the occurrence of endothelial injury and subsequent dysfunction post-HSCT. My work in the lab focuses on development of drugs against TA-TMA and HVOD. With high incidence and mortality rates, these complications undermine and weaken the efficacy of HSCT procedure. Although there are a few drugs available, these drugs are exorbitantly priced debilitating financially the suffering patient. My project revolves around screening of drugs from natural product libraries and then evaluating and testing their potential in the preclinical stage through various invitro and in-vivo models.